

Carlos V P Jardim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384403/publications.pdf>

Version: 2024-02-01

51
papers

1,175
citations

393982

19
h-index

395343

33
g-index

55
all docs

55
docs citations

55
times ranked

1286
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. <i>Circulation</i> , 2009, 119, 1518-1523. | 1.6 | 176 |
| 2 | Cancer-associated thrombosis: the when, how and why. <i>European Respiratory Review</i> , 2019, 28, 180119. | 3.0 | 160 |
| 3 | NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 69-75. | 1.3 | 65 |
| 4 | Pulmonary Arterial Hypertension in the Southern Hemisphere. <i>Chest</i> , 2015, 147, 495-501. | 0.4 | 54 |
| 5 | The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 923-928. | 0.4 | 48 |
| 6 | Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2014, 9, e114101. | 1.1 | 41 |
| 7 | Acute vasodilator test in pulmonary arterial hypertension: Evaluation of two response criteria. <i>Vascular Pharmacology</i> , 2005, 43, 143-147. | 1.0 | 40 |
| 8 | Quality of life as a prognostic marker in pulmonary arterial hypertension. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 130. | 1.0 | 40 |
| 9 | Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2005, 21, 907-911. | 0.9 | 36 |
| 10 | Pulmonary hypertension in lymphangiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 74. | 1.2 | 34 |
| 11 | Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. <i>Journal of Infection</i> , 2014, 68, 90-98. | 1.7 | 33 |
| 12 | Safety and efficacy of sitaxsentan 50 and 100Âmg in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 33-39. | 1.1 | 32 |
| 13 | ValidaÃ§Ã£o de um protocolo para o teste de caminhada de seis minutos em esteira para avaliaÃ§Ã£o de pacientes com hipertensÃ£o arterial pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2009, 35, 423-430. | 0.4 | 29 |
| 14 | II Guidelines for perioperative evaluation of the Brazilian Society of Cardiology. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 1-68. | 0.3 | 29 |
| 15 | DiagnÃ³stico e tratamento da hipertensÃ£o pulmonar: uma atualizaÃ§Ã£o. <i>Jornal Brasileiro De Pneumologia</i> , 2010, 36, 795-811. | 0.4 | 26 |
| 16 | Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated) <i>Tj ETQq0 0 0 rgBT (Overlock_10 Tf 50</i> | 0.8 | 25 |
| 17 | II Diretriz de AvaliaÃ§Ã£o PerioperatÃ³ria da Sociedade Brasileira de Cardiologia. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 1-68. | 0.3 | 23 |
| 18 | 3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 109, 1-104. | 0.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. <i>Clinics</i> , 2018, 73, e216. | 0.6 | 19 |
| 20 | Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2015, 15, 118. | 0.8 | 16 |
| 21 | Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2018, 51, 1800307. | 3.1 | 16 |
| 22 | Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, e195-e197. | 0.3 | 12 |
| 23 | Idiopathic Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 560-567. | 0.8 | 11 |
| 24 | Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. <i>PLoS ONE</i> , 2020, 15, e0233063. | 1.1 | 10 |
| 25 | The Need for National Registries in Rare Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 228-228. | 2.5 | 9 |
| 26 | Reperfusion in acute pulmonary thromboembolism. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 237-243. | 0.4 | 9 |
| 27 | Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a síndrome POEMS. <i>Jornal Brasileiro De Pneumologia</i> , 2009, 35, 804-808. | 0.4 | 9 |
| 28 | Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 556. | 1.5 | 8 |
| 29 | Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180297. | 0.4 | 7 |
| 30 | The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension. <i>Chest</i> , 2006, 130, 1627. | 0.4 | 6 |
| 31 | Electrical impedance tomography in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2021, 16, e0248214. | 1.1 | 6 |
| 32 | Atualização no Tratamento da Hipertensão Arterial Pulmonar. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 750-764. | 0.3 | 6 |
| 33 | O papel dos exames de imagem na avaliação da circulação pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2011, 37, 389-403. | 0.4 | 5 |
| 34 | Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-3. | 0.8 | 4 |
| 35 | Goal-oriented treatment of pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 409-413. | 1.2 | 3 |
| 36 | The global view. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 391-397. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. Clinics, 2020, 75, e1373. | 0.6 | 3 |
| 38 | The importance of the World Symposium on Pulmonary Hypertension. Jornal Brasileiro De Pneumologia, 2018, 44, 173-174. | 0.4 | 3 |
| 39 | Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204. | 0.4 | 3 |
| 40 | Schistosomiasis and Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 143-148. | 0.1 | 2 |
| 41 | Aortopulmonary Window: A Rare Cause of Pulmonary Hypertension. Respiration, 2008, 76, 351-352. | 1.2 | 1 |
| 42 | Letter by Dias et al Regarding Article, "Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy". Circulation, 2010, 122, e1. | 1.6 | 1 |
| 43 | Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35. | 0.1 | 1 |
| 44 | The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , . | | 0 |
| 45 | Comparative Analysis Of The Immunopathology In Idiopathic Versus Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , . | | 0 |
| 46 | Biomarkers in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 59-64. | 0.1 | 0 |
| 47 | Resolução do "shunt" direita-esquerda após uso do sildenafil como tratamento de hipertensão pulmonar primária. Jornal De Pneumologia, 2003, 29, 305-308. | 0.1 | 0 |
| 48 | Schistosomiasis and others in group 5. , 2011, , 491-499. | | 0 |
| 49 | Prognostic value of predicted 6MWD in PAH. , 2015, , . | | 0 |
| 50 | The use of new anticoagulants in CTEPH. , 2017, , . | | 0 |
| 51 | Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. , 2017, , . | | 0 |